PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
EW vs. LLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EW and LLY is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

EW vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Edwards Lifesciences Corporation (EW) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

-30.00%-20.00%-10.00%0.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-19.24%
-11.38%
EW
LLY

Key characteristics

Sharpe Ratio

EW:

-0.13

LLY:

0.65

Sortino Ratio

EW:

0.12

LLY:

1.11

Omega Ratio

EW:

1.02

LLY:

1.15

Calmar Ratio

EW:

-0.10

LLY:

0.84

Martin Ratio

EW:

-0.28

LLY:

2.11

Ulcer Index

EW:

20.04%

LLY:

9.56%

Daily Std Dev

EW:

41.50%

LLY:

30.81%

Max Drawdown

EW:

-54.32%

LLY:

-68.27%

Current Drawdown

EW:

-46.54%

LLY:

-20.95%

Fundamentals

Market Cap

EW:

$41.45B

LLY:

$671.56B

EPS

EW:

$2.59

LLY:

$9.26

PE Ratio

EW:

27.14

LLY:

80.64

PEG Ratio

EW:

6.52

LLY:

0.70

Total Revenue (TTM)

EW:

$4.34B

LLY:

$31.51B

Gross Profit (TTM)

EW:

$3.39B

LLY:

$25.63B

EBITDA (TTM)

EW:

$1.24B

LLY:

$9.48B

Returns By Period

In the year-to-date period, EW achieves a -5.63% return, which is significantly lower than LLY's -1.87% return. Over the past 10 years, EW has underperformed LLY with an annualized return of 12.52%, while LLY has yielded a comparatively higher 29.27% annualized return.


EW

YTD

-5.63%

1M

-5.75%

6M

-18.59%

1Y

-5.36%

5Y*

-2.57%

10Y*

12.52%

LLY

YTD

-1.87%

1M

-2.70%

6M

-10.48%

1Y

21.25%

5Y*

42.24%

10Y*

29.27%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EW vs. LLY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EW
The Risk-Adjusted Performance Rank of EW is 3939
Overall Rank
The Sharpe Ratio Rank of EW is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of EW is 3636
Sortino Ratio Rank
The Omega Ratio Rank of EW is 3838
Omega Ratio Rank
The Calmar Ratio Rank of EW is 4141
Calmar Ratio Rank
The Martin Ratio Rank of EW is 4242
Martin Ratio Rank

LLY
The Risk-Adjusted Performance Rank of LLY is 6868
Overall Rank
The Sharpe Ratio Rank of LLY is 7070
Sharpe Ratio Rank
The Sortino Ratio Rank of LLY is 6363
Sortino Ratio Rank
The Omega Ratio Rank of LLY is 6363
Omega Ratio Rank
The Calmar Ratio Rank of LLY is 7777
Calmar Ratio Rank
The Martin Ratio Rank of LLY is 6868
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EW vs. LLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Edwards Lifesciences Corporation (EW) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for EW, currently valued at -0.13, compared to the broader market-2.000.002.00-0.130.65
The chart of Sortino ratio for EW, currently valued at 0.12, compared to the broader market-4.00-2.000.002.004.006.000.121.11
The chart of Omega ratio for EW, currently valued at 1.02, compared to the broader market0.501.001.502.001.021.15
The chart of Calmar ratio for EW, currently valued at -0.10, compared to the broader market0.002.004.006.00-0.100.84
The chart of Martin ratio for EW, currently valued at -0.28, compared to the broader market-10.000.0010.0020.0030.00-0.282.11
EW
LLY

The current EW Sharpe Ratio is -0.13, which is lower than the LLY Sharpe Ratio of 0.65. The chart below compares the historical Sharpe Ratios of EW and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00AugustSeptemberOctoberNovemberDecember2025
-0.13
0.65
EW
LLY

Dividends

EW vs. LLY - Dividend Comparison

EW has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.69%.


TTM20242023202220212020201920182017201620152014
EW
Edwards Lifesciences Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.69%0.67%0.78%1.07%1.23%1.75%1.96%1.95%2.46%2.77%2.37%2.84%

Drawdowns

EW vs. LLY - Drawdown Comparison

The maximum EW drawdown since its inception was -54.32%, smaller than the maximum LLY drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for EW and LLY. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-46.54%
-20.95%
EW
LLY

Volatility

EW vs. LLY - Volatility Comparison

The current volatility for Edwards Lifesciences Corporation (EW) is 5.81%, while Eli Lilly and Company (LLY) has a volatility of 9.44%. This indicates that EW experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
5.81%
9.44%
EW
LLY

Financials

EW vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Edwards Lifesciences Corporation and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab